文献速递其他结缔组织病

美国西南部原住民中他汀相关免疫介导坏死性肌病患病率与发病率增加

Increased prevalence and incidence of statin-associated immune-mediated necrotizing myopathy in Native Americans.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该回顾性单中心研究纳入148例特发性炎症性肌病(IIM)患者,其中33例自认为原住民、115例为非原住民,比较两组他汀相关免疫介导坏死性肌病(IMNM)的特征与结局。原住民组抗HMGCR抗体阳性率及他汀相关IMNM的估计患病率和发病率均高于非原住民组,但两组临床结局与治疗无显著差异。

要点

  • 原住民IIM患者他汀暴露比例(71.9% vs 40.0%,P=0.002)及抗HMGCR抗体阳性率(46.9% vs 16.5%,P=0.0007)均高于非原住民。
  • 原住民他汀相关IMNM估计患病率为182例/10^6人口,非原住民为30.6例/10^6人口。
  • 原住民他汀相关IMNM估计发病率为66.4例/年/10^6人口,非原住民为7.5例/年/10^6人口。

核心结论

  • 他汀相关IMNM在美国西南部原住民中显著更常见,但两组接受的治疗与结局似乎相似。

研究设计与样本

  • 回顾性单中心研究,共纳入148例IIM患者,其中33例自认为原住民、115例为非原住民,IIM诊断采用标准标准,他汀相关IMNM诊断需抗HMGCR抗体阳性。

主要发现

  • 原住民IIM患者较非原住民有更低的身体质量指数、肌炎损害指数和炎症性关节炎,但高脂血症(75% vs 49.6%,P=0.015)、他汀暴露(71.9% vs 40.0%,P=0.002)、糖尿病(62.5% vs 34.8%,P=0.044)及食管运动障碍(93.8% vs 77.4%,P=0.042)更多。
  • 原住民较非原住民更常见抗RNP抗体(15.6% vs 2.6%,P=0.013)和抗HMGCR抗体(46.9% vs 16.5%,P=0.0007)。
  • 原住民他汀相关IMNM估计患病率为182例/10^6人口 vs 非原住民30.6例/10^6人口,估计发病率为66.4例/年/10^6人口 vs 7.5例/年/10^6人口。
  • 两组临床结局与接受的治疗无显著差异。

关键数值与推荐

  • IIM诊断采用标准标准,他汀相关IMNM诊断要求抗HMGCR抗体阳性。
  • 原住民高脂血症75% vs 非原住民49.6%(P=0.015),他汀暴露71.9% vs 40.0%(P=0.002),糖尿病62.5% vs 34.8%(P=0.044),食管运动障碍93.8% vs 77.4%(P=0.042)。
  • 原住民抗RNP抗体15.6% vs 非原住民2.6%(P=0.013),抗HMGCR抗体46.9% vs 16.5%(P=0.0007)。
  • 原住民他汀相关IMNM估计患病率182例/10^6人口 vs 非原住民30.6例/10^6人口,估计发病率66.4例/年/10^6人口 vs 7.5例/年/10^6人口。

临床怎么用

  • 在美国西南部原住民IIM患者中,他汀相关IMNM显著更常见,临床识别时需考虑该人群的抗HMGCR抗体检测。
  • 原住民与非原住民他汀相关IMNM接受的治疗与结局似乎相似。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Statin-associated immune-mediated necrotizing myopathy (IMNM) is an idiopathic inflammatory myopathy (IIM) associated with anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies. This research determined the characteristics and outcomes of Native Americans vs non-Native Americans (non-NA) diagnosed with IIM and IMNM from the American Southwest. METHODS: In this retrospective single-institution study, IIM diagnosis was established with standard criteria, and statin-associated IMNM diagnosis required the presence of anti-HMGCR antibodies. Of 148 subjects with IIM, 33 self-identified as Native American and 115 as non-NA. The proportion of IIM and IMNM in each group, clinical and laboratory parameters, and the outcomes were compared. RESULTS: Compared with non-NA, Native Americans with IIM had a lower body mass index, myositis damage index and inflammatory arthritis, but more hyperlipidemia (75% vs 49.6%; P = 0.015), statin exposure (71.9% vs 40.0%; P = 0.002), diabetes mellitus (DM) (62.5% vs 34.8%; P = 0.044) and esophageal dysmotility (93.8% vs 77.4%; P = 0.042). Native Americans more frequently expressed anti-RNP antibody (15.6% vs 2.6%, P = 0.013) and anti-HMGCR antibody (46.9% vs 16.5%, P = 0.0007). The estimated prevalence of statin-associated IMNM in Native Americans vs non-NA was 182 vs 30.6 cases/106 population, and incidence was 66.4 vs 7.5 cases/year/106 population. There were no significant differences in the clinical outcomes and treatment received between the two groups. CONCLUSION: Statin-associated IMNM is significantly more common in Native Americans in the American Southwest. The treatments received and outcomes of statin-associated IMNM in Native Americans and non-NA seem to be similar. The underlying genetic and environmental factors predisposing to IMNM in these populations require further study.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dinh TN, Inga EE, Waters YM, et al. Increased prevalence and incidence of statin-associated immune-mediated necrotizing myopathy in Native Americans. Rheumatology (Oxford). 2026. PMID: 41270801. doi:10.1093/rheumatology/keaf618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。